Research identifies PLK4 as promising therapeutic target for TP53 mutated acute myeloid leukemia

A research team led by Professor Anskar Leung Yu-hung, from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has identified PLK4 as a novel therapeutic target for acute myeloid leukemia (AML) carrying the TP53 mutation. AML is a deadly disease, for which there is currently a lack of effective treatment options.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.